The CSF Immune Response in HIV-1-Associated Cryptococcal Meningitis: Macrophage Activation, Correlates of Disease Severity, and Effect of Antiretroviral Therapy.
Identifieur interne : 000A78 ( PubMed/Corpus ); précédent : 000A77; suivant : 000A79The CSF Immune Response in HIV-1-Associated Cryptococcal Meningitis: Macrophage Activation, Correlates of Disease Severity, and Effect of Antiretroviral Therapy.
Auteurs : James E. Scriven ; Lisa M. Graham ; Charlotte Schutz ; Thomas J. Scriba ; Katalin A. Wilkinson ; Robert J. Wilkinson ; David R. Boulware ; Britta C. Urban ; Graeme Meintjes ; David G. LallooSource :
- Journal of acquired immune deficiency syndromes (1999) [ 1944-7884 ] ; 2017.
English descriptors
- KwdEn :
- AIDS-Related Opportunistic Infections (cerebrospinal fluid), AIDS-Related Opportunistic Infections (complications), AIDS-Related Opportunistic Infections (drug therapy), AIDS-Related Opportunistic Infections (immunology), Adult, CD4-CD8 Ratio, Cytokines (cerebrospinal fluid), HIV Infections (cerebrospinal fluid), HIV Infections (complications), HIV Infections (drug therapy), HIV Infections (immunology), HIV-1 (drug effects), HIV-1 (immunology), Humans, Immune Reconstitution Inflammatory Syndrome (etiology), Immune Reconstitution Inflammatory Syndrome (immunology), Macrophage Activation (drug effects), Meningitis, Cryptococcal (cerebrospinal fluid), Meningitis, Cryptococcal (complications), Meningitis, Cryptococcal (immunology), Meningitis, Cryptococcal (pathology), Prospective Studies, Severity of Illness Index.
- MESH :
- chemical , cerebrospinal fluid : Cytokines.
- cerebrospinal fluid : AIDS-Related Opportunistic Infections, HIV Infections, Meningitis, Cryptococcal.
- complications : AIDS-Related Opportunistic Infections, HIV Infections, Meningitis, Cryptococcal.
- drug effects : HIV-1, Macrophage Activation.
- drug therapy : AIDS-Related Opportunistic Infections, HIV Infections.
- etiology : Immune Reconstitution Inflammatory Syndrome.
- immunology : AIDS-Related Opportunistic Infections, HIV Infections, HIV-1, Immune Reconstitution Inflammatory Syndrome, Meningitis, Cryptococcal.
- pathology : Meningitis, Cryptococcal.
- Adult, CD4-CD8 Ratio, Humans, Prospective Studies, Severity of Illness Index.
Abstract
Immune modulation may improve outcome in HIV-associated cryptococcal meningitis. Animal studies suggest alternatively activated macrophages are detrimental but human studies are limited. We performed a detailed assessment of the cerebrospinal fluid (CSF) immune response and examined immune correlates of disease severity and poor outcome, and the effects of antiretroviral therapy (ART).
DOI: 10.1097/QAI.0000000000001382
PubMed: 28346317
Links to Exploration step
pubmed:28346317Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The CSF Immune Response in HIV-1-Associated Cryptococcal Meningitis: Macrophage Activation, Correlates of Disease Severity, and Effect of Antiretroviral Therapy.</title><author><name sortKey="Scriven, James E" sort="Scriven, James E" uniqKey="Scriven J" first="James E" last="Scriven">James E. Scriven</name><affiliation><nlm:affiliation>*Clinical Infectious Diseases Research Initiative, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory, South Africa; †Liverpool School of Tropical Medicine, Liverpool, United Kingdom; ‡Wellcome Trust Liverpool Glasgow Centre for Global Health Research, Liverpool, United Kingdom; §Department of Medicine, University of Cape Town and Groote Schuur Hospital, Observatory, South Africa; ‖South African TB Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa; ¶The Francis Crick Institute, Mill Hill Laboratory, The Ridgeway, London, United Kingdom; #Department of Medicine, Imperial College, London, United Kingdom; and **Department of Medicine, University of Minnesota, MN.</nlm:affiliation></affiliation></author><author><name sortKey="Graham, Lisa M" sort="Graham, Lisa M" uniqKey="Graham L" first="Lisa M" last="Graham">Lisa M. Graham</name></author><author><name sortKey="Schutz, Charlotte" sort="Schutz, Charlotte" uniqKey="Schutz C" first="Charlotte" last="Schutz">Charlotte Schutz</name></author><author><name sortKey="Scriba, Thomas J" sort="Scriba, Thomas J" uniqKey="Scriba T" first="Thomas J" last="Scriba">Thomas J. Scriba</name></author><author><name sortKey="Wilkinson, Katalin A" sort="Wilkinson, Katalin A" uniqKey="Wilkinson K" first="Katalin A" last="Wilkinson">Katalin A. Wilkinson</name></author><author><name sortKey="Wilkinson, Robert J" sort="Wilkinson, Robert J" uniqKey="Wilkinson R" first="Robert J" last="Wilkinson">Robert J. Wilkinson</name></author><author><name sortKey="Boulware, David R" sort="Boulware, David R" uniqKey="Boulware D" first="David R" last="Boulware">David R. Boulware</name></author><author><name sortKey="Urban, Britta C" sort="Urban, Britta C" uniqKey="Urban B" first="Britta C" last="Urban">Britta C. Urban</name></author><author><name sortKey="Meintjes, Graeme" sort="Meintjes, Graeme" uniqKey="Meintjes G" first="Graeme" last="Meintjes">Graeme Meintjes</name></author><author><name sortKey="Lalloo, David G" sort="Lalloo, David G" uniqKey="Lalloo D" first="David G" last="Lalloo">David G. Lalloo</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28346317</idno><idno type="pmid">28346317</idno><idno type="doi">10.1097/QAI.0000000000001382</idno><idno type="wicri:Area/PubMed/Corpus">000A78</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000A78</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">The CSF Immune Response in HIV-1-Associated Cryptococcal Meningitis: Macrophage Activation, Correlates of Disease Severity, and Effect of Antiretroviral Therapy.</title><author><name sortKey="Scriven, James E" sort="Scriven, James E" uniqKey="Scriven J" first="James E" last="Scriven">James E. Scriven</name><affiliation><nlm:affiliation>*Clinical Infectious Diseases Research Initiative, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory, South Africa; †Liverpool School of Tropical Medicine, Liverpool, United Kingdom; ‡Wellcome Trust Liverpool Glasgow Centre for Global Health Research, Liverpool, United Kingdom; §Department of Medicine, University of Cape Town and Groote Schuur Hospital, Observatory, South Africa; ‖South African TB Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa; ¶The Francis Crick Institute, Mill Hill Laboratory, The Ridgeway, London, United Kingdom; #Department of Medicine, Imperial College, London, United Kingdom; and **Department of Medicine, University of Minnesota, MN.</nlm:affiliation></affiliation></author><author><name sortKey="Graham, Lisa M" sort="Graham, Lisa M" uniqKey="Graham L" first="Lisa M" last="Graham">Lisa M. Graham</name></author><author><name sortKey="Schutz, Charlotte" sort="Schutz, Charlotte" uniqKey="Schutz C" first="Charlotte" last="Schutz">Charlotte Schutz</name></author><author><name sortKey="Scriba, Thomas J" sort="Scriba, Thomas J" uniqKey="Scriba T" first="Thomas J" last="Scriba">Thomas J. Scriba</name></author><author><name sortKey="Wilkinson, Katalin A" sort="Wilkinson, Katalin A" uniqKey="Wilkinson K" first="Katalin A" last="Wilkinson">Katalin A. Wilkinson</name></author><author><name sortKey="Wilkinson, Robert J" sort="Wilkinson, Robert J" uniqKey="Wilkinson R" first="Robert J" last="Wilkinson">Robert J. Wilkinson</name></author><author><name sortKey="Boulware, David R" sort="Boulware, David R" uniqKey="Boulware D" first="David R" last="Boulware">David R. Boulware</name></author><author><name sortKey="Urban, Britta C" sort="Urban, Britta C" uniqKey="Urban B" first="Britta C" last="Urban">Britta C. Urban</name></author><author><name sortKey="Meintjes, Graeme" sort="Meintjes, Graeme" uniqKey="Meintjes G" first="Graeme" last="Meintjes">Graeme Meintjes</name></author><author><name sortKey="Lalloo, David G" sort="Lalloo, David G" uniqKey="Lalloo D" first="David G" last="Lalloo">David G. Lalloo</name></author></analytic><series><title level="j">Journal of acquired immune deficiency syndromes (1999)</title><idno type="eISSN">1944-7884</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>AIDS-Related Opportunistic Infections (cerebrospinal fluid)</term><term>AIDS-Related Opportunistic Infections (complications)</term><term>AIDS-Related Opportunistic Infections (drug therapy)</term><term>AIDS-Related Opportunistic Infections (immunology)</term><term>Adult</term><term>CD4-CD8 Ratio</term><term>Cytokines (cerebrospinal fluid)</term><term>HIV Infections (cerebrospinal fluid)</term><term>HIV Infections (complications)</term><term>HIV Infections (drug therapy)</term><term>HIV Infections (immunology)</term><term>HIV-1 (drug effects)</term><term>HIV-1 (immunology)</term><term>Humans</term><term>Immune Reconstitution Inflammatory Syndrome (etiology)</term><term>Immune Reconstitution Inflammatory Syndrome (immunology)</term><term>Macrophage Activation (drug effects)</term><term>Meningitis, Cryptococcal (cerebrospinal fluid)</term><term>Meningitis, Cryptococcal (complications)</term><term>Meningitis, Cryptococcal (immunology)</term><term>Meningitis, Cryptococcal (pathology)</term><term>Prospective Studies</term><term>Severity of Illness Index</term></keywords><keywords scheme="MESH" type="chemical" qualifier="cerebrospinal fluid" xml:lang="en"><term>Cytokines</term></keywords><keywords scheme="MESH" qualifier="cerebrospinal fluid" xml:lang="en"><term>AIDS-Related Opportunistic Infections</term><term>HIV Infections</term><term>Meningitis, Cryptococcal</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>AIDS-Related Opportunistic Infections</term><term>HIV Infections</term><term>Meningitis, Cryptococcal</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>HIV-1</term><term>Macrophage Activation</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>AIDS-Related Opportunistic Infections</term><term>HIV Infections</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Immune Reconstitution Inflammatory Syndrome</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>AIDS-Related Opportunistic Infections</term><term>HIV Infections</term><term>HIV-1</term><term>Immune Reconstitution Inflammatory Syndrome</term><term>Meningitis, Cryptococcal</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Meningitis, Cryptococcal</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>CD4-CD8 Ratio</term><term>Humans</term><term>Prospective Studies</term><term>Severity of Illness Index</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Immune modulation may improve outcome in HIV-associated cryptococcal meningitis. Animal studies suggest alternatively activated macrophages are detrimental but human studies are limited. We performed a detailed assessment of the cerebrospinal fluid (CSF) immune response and examined immune correlates of disease severity and poor outcome, and the effects of antiretroviral therapy (ART).</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28346317</PMID><DateCreated><Year>2017</Year><Month>03</Month><Day>27</Day></DateCreated><DateCompleted><Year>2017</Year><Month>09</Month><Day>19</Day></DateCompleted><DateRevised><Year>2017</Year><Month>09</Month><Day>22</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1944-7884</ISSN><JournalIssue CitedMedium="Internet"><Volume>75</Volume><Issue>3</Issue><PubDate><Year>2017</Year><Month>Jul</Month><Day>01</Day></PubDate></JournalIssue><Title>Journal of acquired immune deficiency syndromes (1999)</Title><ISOAbbreviation>J. Acquir. Immune Defic. Syndr.</ISOAbbreviation></Journal><ArticleTitle>The CSF Immune Response in HIV-1-Associated Cryptococcal Meningitis: Macrophage Activation, Correlates of Disease Severity, and Effect of Antiretroviral Therapy.</ArticleTitle><Pagination><MedlinePgn>299-307</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/QAI.0000000000001382</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Immune modulation may improve outcome in HIV-associated cryptococcal meningitis. Animal studies suggest alternatively activated macrophages are detrimental but human studies are limited. We performed a detailed assessment of the cerebrospinal fluid (CSF) immune response and examined immune correlates of disease severity and poor outcome, and the effects of antiretroviral therapy (ART).</AbstractText><AbstractText Label="METHODOLOGY" NlmCategory="METHODS">We enrolled persons ≥18 years with first episode of HIV-associated cryptococcal meningitis. CSF immune response was assessed using flow cytometry and multiplex cytokine analysis. Principal component analysis was used to examine relationships between immune response, fungal burden, intracranial pressure and mortality, and the effects of recent ART initiation (<12 weeks).</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">CSF was available from 57 persons (median CD4 34/μL). CD206 (alternatively activated macrophage marker) was expressed on 54% CD14 and 35% CD14 monocyte-macrophages. High fungal burden was not associated with CD206 expression but with a paucity of CD4, CD8, and CD4CD8 T cells and lower interleukin-6, G-CSF, and interleukin-5 concentrations. High intracranial pressure (≥30 cm H2O) was associated with fewer T cells, a higher fungal burden, and larger Cryptococcus organisms. Mortality was associated with reduced interferon-gamma concentrations and CD4CD8 T cells but lost statistical significance when adjusted for multiple comparisons. Recent ART was associated with increased CSF CD4/CD8 ratio and a significantly increased macrophage expression of CD206.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Paucity of CSF T cell infiltrate rather than alternative macrophage activation was associated with severe disease in HIV-associated cryptococcosis. ART had a pronounced effect on the immune response at the site of disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Scriven</LastName><ForeName>James E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>*Clinical Infectious Diseases Research Initiative, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory, South Africa; †Liverpool School of Tropical Medicine, Liverpool, United Kingdom; ‡Wellcome Trust Liverpool Glasgow Centre for Global Health Research, Liverpool, United Kingdom; §Department of Medicine, University of Cape Town and Groote Schuur Hospital, Observatory, South Africa; ‖South African TB Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa; ¶The Francis Crick Institute, Mill Hill Laboratory, The Ridgeway, London, United Kingdom; #Department of Medicine, Imperial College, London, United Kingdom; and **Department of Medicine, University of Minnesota, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Graham</LastName><ForeName>Lisa M</ForeName><Initials>LM</Initials></Author><Author ValidYN="Y"><LastName>Schutz</LastName><ForeName>Charlotte</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Scriba</LastName><ForeName>Thomas J</ForeName><Initials>TJ</Initials></Author><Author ValidYN="Y"><LastName>Wilkinson</LastName><ForeName>Katalin A</ForeName><Initials>KA</Initials></Author><Author ValidYN="Y"><LastName>Wilkinson</LastName><ForeName>Robert J</ForeName><Initials>RJ</Initials></Author><Author ValidYN="Y"><LastName>Boulware</LastName><ForeName>David R</ForeName><Initials>DR</Initials></Author><Author ValidYN="Y"><LastName>Urban</LastName><ForeName>Britta C</ForeName><Initials>BC</Initials></Author><Author ValidYN="Y"><LastName>Meintjes</LastName><ForeName>Graeme</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Lalloo</LastName><ForeName>David G</ForeName><Initials>DG</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>098316</GrantID><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>U01 AI089244</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>104803</GrantID><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>094013</GrantID><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>079082</GrantID><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Acquir Immune Defic Syndr</MedlineTA><NlmUniqueID>100892005</NlmUniqueID><ISSNLinking>1525-4135</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CitationSubset>X</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Trends Microbiol. 2001 Jun;9(6):273-8</RefSource><PMID Version="1">11390242</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mucosal Immunol. 2014 Sep;7(5):1116-26</RefSource><PMID Version="1">24472847</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Infect Dis. 1974 Jul;130(1):74-7</RefSource><PMID Version="1">4834923</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Immunol. 2005 Feb 1;174(3):1746-50</RefSource><PMID Version="1">15661940</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Microbiol Immunol. 1995;39(2):135-43</RefSource><PMID Version="1">7783686</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Infect Dis. 2015 May 15;211(10):1597-606</RefSource><PMID Version="1">25492918</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2009 Mar 27;23(6):701-6</RefSource><PMID Version="1">19279443</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Infect Dis. 2016 Aug;16(8):891-2</RefSource><PMID Version="1">27477977</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2009 Feb 20;23(4):525-30</RefSource><PMID Version="1">19182676</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cytometry B Clin Cytom. 2011 Jan;80(1):43-50</RefSource><PMID Version="1">20632412</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Acta Paediatr. 1995 Nov;84(11):1268-70</RefSource><PMID Version="1">8580624</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Immunol Methods. 2012 Jan 31;375(1-2):196-206</RefSource><PMID Version="1">22075274</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Infect Dis. 2016 Jul;16(7):809-18</RefSource><PMID Version="1">26971081</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Infect Dis. 2014 Jan 1;209(1):74-82</RefSource><PMID Version="1">23945372</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Immunol. 2003 Aug;33(8):2223-32</RefSource><PMID Version="1">12884297</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2013 Jun 18;8(6):e66188</RefSource><PMID Version="1">23822975</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Infect Dis. 2010 Nov;10(11):791-802</RefSource><PMID Version="1">21029993</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Pathol. 2009 Feb;174(2):486-96</RefSource><PMID Version="1">19147811</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Infect Immun. 1998 Feb;66(2):664-9</RefSource><PMID Version="1">9453624</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Immunol. 2006 Jul;7(7):681-5</RefSource><PMID Version="1">16785881</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Infect Immun. 2013 Jan;81(1):90-8</RefSource><PMID Version="1">23090956</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Biotechnol. 2008 Mar;26(3):303-4</RefSource><PMID Version="1">18327243</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2010 Jan 28;24(3):405-10</RefSource><PMID Version="1">19952714</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Hyg. 1955 Nov;62(3):227-32</RefSource><PMID Version="1">13268414</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Infect Dis. 2005 Aug 15;192(4):681-4</RefSource><PMID Version="1">16028138</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Methods. 2010 Apr;50(4):323-35</RefSource><PMID Version="1">20079843</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Retrovirology. 2010 Apr 09;7:33</RefSource><PMID Version="1">20380696</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS Pathog. 2006 Nov;2(11):e120</RefSource><PMID Version="1">17096589</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>BMC Infect Dis. 2010 Mar 15;10:67</RefSource><PMID Version="1">20230635</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Trop Med Int Health. 2010 Aug;15(8):910-7</RefSource><PMID Version="1">20573075</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Virology. 2006 May 25;349(1):112-20</RefSource><PMID Version="1">16564558</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Leukoc Biol. 1995 Jul;58(1):40-8</RefSource><PMID Version="1">7542306</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Invest. 2010 May;120(5):1389-92</RefSource><PMID Version="1">20424319</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Br Med Bull. 2005 Apr 18;72:99-118</RefSource><PMID Version="1">15838017</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Pediatrics. 2001 May;107(5):E66</RefSource><PMID Version="1">11331716</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Rev Immunol. 2003 Jan;3(1):23-35</RefSource><PMID Version="1">12511873</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Bioinformatics. 2001 Jun;17(6):520-5</RefSource><PMID Version="1">11395428</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neuroimmunol. 2006 Jun;175(1-2):160-8</RefSource><PMID Version="1">16624421</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Microbiol. 2016 Mar;54(3):802-4</RefSource><PMID Version="1">26719441</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS Pathog. 2015 Apr 08;11(4):e1004754</RefSource><PMID Version="1">25853653</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D017088" MajorTopicYN="N">AIDS-Related Opportunistic Infections</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016516" MajorTopicYN="N">CD4-CD8 Ratio</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015658" MajorTopicYN="N">HIV Infections</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015497" MajorTopicYN="N">HIV-1</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054019" MajorTopicYN="N">Immune Reconstitution Inflammatory Syndrome</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008262" MajorTopicYN="N">Macrophage Activation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016919" MajorTopicYN="N">Meningitis, Cryptococcal</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>07</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>3</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>9</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>3</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28346317</ArticleId><ArticleId IdType="doi">10.1097/QAI.0000000000001382</ArticleId><ArticleId IdType="pmc">PMC5469563</ArticleId><ArticleId IdType="mid">EMS71997</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaSubSaharaV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A78 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000A78 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= SidaSubSaharaV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:28346317
|texte= The CSF Immune Response in HIV-1-Associated Cryptococcal Meningitis: Macrophage Activation, Correlates of Disease Severity, and Effect of Antiretroviral Therapy.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:28346317" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a SidaSubSaharaV1
| This area was generated with Dilib version V0.6.32. |  |